Nouscom Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 38

Employees
  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $39.8M

  • Investors
  • 4

Nouscom General Information

Description

Developer of an immunotherapy platform designed to develop engineered viral vector vaccines for the treatment of cancer. The company's platform utilizes a portfolio of uniquely engineered viral vectors optimized for the efficient expression of long strings of tumor neoantigens and comprises a toolkit for the induction of broad and potent antitumor T-cell responses, enabling patients to enhance cancer-specific cellular immunity.

Contact Information

Website
www.nouscom.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Bäumleingasse 18
  • 4051 Basel
  • Switzerland
+41 061 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nouscom Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 11-Sep-2020 $39.8M 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 06-Nov-2017 000.00 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 17-May-2016 $13.6M $13.6M Completed Startup
To view Nouscom’s complete valuation and funding history, request access »

Nouscom Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series A 00,000 00.000000 0000.00 0000.00 00 0000.00 0.000
To view Nouscom’s complete cap table history, request access »

Nouscom Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an immunotherapy platform designed to develop engineered viral vector vaccines for the treatment of cancer.
Drug Discovery
Basel, Switzerland
38 As of 2022
00000
0000 0000-00-00
00000000000 00000

000000

ng elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
Philadelphia, PA
00 As of 0000
00000
000000000 00000

00000

, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 000000000
Geneva, Switzerland
00 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nouscom Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Carisma Therapeutics Venture Capital-Backed Philadelphia, PA 00 00000 000000000 00000
00000 00000 000000 Private Equity-Backed Geneva, Switzerland 00 00000 00000000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
0000000 Venture Capital-Backed Basel, Switzerland 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
You’re viewing 5 of 25 competitors. Get the full list »

Nouscom Patents

Nouscom Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3703744-A1 Vaccine t cell enhancer Pending 03-Nov-2017 0000000000
US-20210363201-A1 Vaccine t cell enhancer Pending 03-Nov-2017 0000000000 0
CA-3078692-A1 Vaccine t cell enhancer Pending 03-Nov-2017 0000000000
AU-2018358019-A1 Vaccine t cell enhancer Pending 03-Nov-2017 0000000000
AU-2018356538-A1 Eukaryotic cell line Pending 25-Oct-2017 C12N15/86
To view Nouscom’s complete patent history, request access »

Nouscom Executive Team (12)

Name Title Board Seat Contact Info
Marina Udier Ph.D Chief Executive Officer & Board Member
Richard Davis Ph.D Chief Operating Officer
Stefano Colloca MD Co-Founder, Chief Technical Officer & Advisor
Elisa Scarselli MD Co-Founder & Chief Scientific Officer
Cinzia Traboni Ph.D Co-Founder & Head of Regulatory Affairs
You’re viewing 5 of 12 executive team members. Get the full list »

Nouscom Board Members (11)

Name Representing Role Since
Genghis Lloyd-Harris Ph.D Abingworth Board Member 000 0000
Gianni Gromo Ph.D Versant Ventures Board Observer 000 0000
Göran Ando MD Self Chairman 000 0000
Guido Magni MD Versant Ventures Board Member 000 0000
Jean-Paul Prieels Ph.D Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Nouscom Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nouscom Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Abingworth Venture Capital Minority 000 0000 000000 0
EQT Life Sciences Venture Capital Minority 000 0000 000000 0
Versant Ventures Venture Capital Minority 000 0000 000000 0
To view Nouscom’s complete investors history, request access »